Evidence map›Paper›PMID 26210757›Full record

ArticleAmerican journal of obstetrics and gynecology2015

The female urinary microbiome in urgency urinary incontinence.

Meghan M Pearce, Michael J Zilliox, Amy B Rosenfeld, Krystal J Thomas-White, Holly E Richter, Charles W Nager, Anthony G Visco, Ingrid E Nygaard, Matthew D Barber, Joseph Schaffer and 11 more

6 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 185 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed, 6 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02868463 completednot on this mapstarted 2016, after this paper: background citation

Bladder Environment: Microbiome Oxygen Relationship

TypeobservationalSponsorLoyola UniversityRan2016 to 2017Enrolled115ConditionsUrinary Incontinence, UTI's
NCT04090190 phase4completednot on this mapstarted 2019, after this paper: background citation

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

TypeinterventionalSponsorBrigham and Women's HospitalRan2019 to 2021Enrolled20ConditionsUrinary Incontinence, Urgency UrinaryArmsOxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
NCT04401176 phase2completednot on this mapstarted 2020, after this paper: background citation

A Randomized Trial of Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome

TypeinterventionalSponsorWalter Reed National Military Medical CenterRan2020 to 2023Enrolled58ConditionsInterstitial Cystitis, Bladder Pain SyndromeArmsHeparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A
NCT05414305 phase2completednot on this mapstarted 2020, after this paper: background citation

The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

TypeinterventionalSponsorWalter Reed National Military Medical CenterRan2020 to 2023Enrolled29ConditionsInterstitial Cystitis, Bladder Pain Syndrome, Microbial ColonizationArmsHeparin & Alkalinized Lidocaine Bladder Instillation
NCT05557279 phase2completednot on this mapstarted 2023, after this paper: background citation

Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study

TypeinterventionalSponsorLoyola UniversityRan2023 to 2025Enrolled53ConditionsOveractive BladderArms500 mg NDS-446
NCT07535619 recruitingnot on this mapstarted 2022, after this paper: background citation

The Voided Urinary, Perineal, and Faecal Microbiota Among Children and Adolescents With Overactive Bladder and Daytime Urinary Incontinence and Healthy Children and Adolescents - the PpUF-study.

TypeobservationalSponsorAalborg University HospitalRan2022 to 2028Enrolled110ConditionsUrinary Incontinence, Daytime Wetting, Urination Disorders, Urologic Diseases
3 · Its place in the literature

Who cites it

185 citing papers in PubMed, 6 syntheses or guidelines pooled it, 295 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Article
  18. The emerging role of the microbiome in bladder cancer: prognostic implications and treatment response.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Review
  19. Article
  20. Article

125 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 2 countries.

Meghan M PearceDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Michael J ZillioxDepartment of Molecular Pharmacology and Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Amy B RosenfeldMicrobiology and Immunology Department, Hammer Health Sciences, College of Physicians and Surgeons, Columbia University, New York, NY.
Krystal J Thomas-WhiteDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Holly E RichterDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham School of Medicine, Birmingham, AL.
Charles W NagerDepartment of Reproductive Medicine, UC San Diego Health System, San Diego, CA.
Anthony G ViscoDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC.
Ingrid E NygaardDepartment of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT.
Matthew D BarberObstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, OH.
Joseph SchafferDepartment of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX.
Pamela MoalliDepartment of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA.
Vivian W SungDepartment of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI.
Ariana L SmithDepartment of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Rebecca RogersDepartment of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM.
Tracy L NolenRTI International, Research Triangle Park, NC.
Dennis WallaceRTI International, Research Triangle Park, NC.
Susan F MeikleContraception and Reproductive Health Branch, Center for Population Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Xiaowu GaiDepartment of Molecular Pharmacology and Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Alan J WolfeDepartments of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL.
Linda BrubakerDepartments of Obstetrics and Gynecology and Urology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL. Electronic address: lbrubaker@luc.edu.
Pelvic Floor Disorders Network
Loyola University Chicago · USRTI International · USBrown University · USCleveland Clinic · USColumbia University · USDuke Medical Center · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USThe University of Texas Southwestern Medical Center · USUC San Diego Health System · USUniversity of Alabama at Birmingham · USUniversity of New Mexico · USUniversity of Pennsylvania · USUniversity of Pittsburgh · USUniversity of Utah · US

Funding

Pelvic floor Disorders Network-Data Coordinating CenterU01HD041249 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WEI, JOHN T · 2001 to 2010
$19.8M
Pelvic Floor Disorders Network Data Coordinating Center (U01)U01HD069031 · NICHD · RESEARCH TRIANGLE INSTITUTE · PI GANTZ, MARIE G · 2011 to 2015
$19.7M
Perioperative Pelvic Floor Rehab: A Rrandomized TrialU10HD041261 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RICHTER, HOLLY E · 2001 to 2015
$5.1M
The Pelvic Floor Disorders NetworkU10HD041250 · NICHD · LOYOLA UNIVERSITY CHICAGO · PI BRUBAKER, LINDA · 2001 to 2015
$3.8M
Pelvic Floor Disorders NetworkU10HD054214 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LUKACZ, EMILY S. · 2006 to 2015
$3.3M
The Cleveland Clinic Clinical SiteU10HD054215 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI BARBER, MATTHEW D · 2006 to 2015
$3.2M
Pelvic Floor Disorders Network Clinical Sites (UG1)UG1HD069010 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI Heidi S Harvie · 2016 to 2026
$3.0M
Loyola Research Computing CoreG20RR030939 · NCRR · LOYOLA UNIVERSITY CHICAGO · PI KENNEDY, RICHARD H. · 2010 to 2010
$2.7M
NICHD Pelvic Floor Disorders Network Clinical Sites (U10)U10HD054241 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI SCHAFFER, JOSEPH I · 2006 to 2015
$1.9M
Pelvic Floor Disorders Network Clinical Sites (U10)U10HD069010 · NICHD · UNIVERSITY OF PENNSYLVANIA · PI ARYA, LILY A · 2011 to 2015
$1.7M
Brown/WIH Pelvic Floor Disorders Network SiteU10HD069013 · NICHD · WOMEN AND INFANTS HOSPITAL-RHODE ISLAND · PI SUNG, VIVIAN W · 2011 to 2015
$1.6M
Pittsburgh Pelvic Floor Research ProgramU10HD069006 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI ZYCZYNSKI, HALINA M · 2011 to 2015
$1.6M
NCRR NIH HHS 1G20RR030939-0 1NCRR NIH HHS G20 RR030939NICHD NIH HHS 1-U01-HD069010-01NICHD NIH HHS 1-U10-HD069006-01NICHD NIH HHS 2-U10-HD041261-11NICHD NIH HHS 2-U10-HD04267-12NICHD NIH HHS 2-U10-HD054214-06NICHD NIH HHS 2-U10-HD054215-06NICHD NIH HHS 2-U10-HD054241-06NICHD NIH HHS U01 HD041249NICHD NIH HHS U01 HD069031NICHD NIH HHS U01 HD069031RTNICHD NIH HHS U10 HD041250NICHD NIH HHS U10 HD041261NICHD NIH HHS U10 HD054136NICHD NIH HHS U10-HD054136NICHD NIH HHS U10 HD054214NICHD NIH HHS U10 HD054215NICHD NIH HHS U10 HD054241NICHD NIH HHS U10 HD069006NICHD NIH HHS U10 HD069010NICHD NIH HHS U10 HD069013NICHD NIH HHS U10 HD069025NICHD NIH HHS U10-HD41249NICHD NIH HHS UG1 HD069010
6 · The paper itself

Abstract

objectiveThe purpose of this study was to characterize the urinary microbiota in women who are planning treatment for urgency urinary incontinence and to describe clinical associations with urinary symptoms, urinary tract infection, and treatment outcomes. STUDY

designCatheterized urine samples were collected from multisite randomized trial participants who had no clinical evidence of urinary tract infection; 16S ribosomal RNA gene sequencing was used to dichotomize participants as either DNA sequence-positive or sequence-negative. Associations with demographics, urinary symptoms, urinary tract infection risk, and treatment outcomes were determined. In sequence-positive samples, microbiotas were characterized on the basis of their dominant microorganisms.

resultsMore than one-half (51.1%; 93/182) of the participants' urine samples were sequence-positive. Sequence-positive participants were younger (55.8 vs 61.3 years old; P = .0007), had a higher body mass index (33.7 vs 30.1 kg/m(2); P = .0009), had a higher mean baseline daily urgency urinary incontinence episodes (5.7 vs 4.2 episodes; P < .0001), responded better to treatment (decrease in urgency urinary incontinence episodes, -4.4 vs -3.3; P = .0013), and were less likely to experience urinary tract infection (9% vs 27%; P = .0011). In sequence-positive samples, 8 major bacterial clusters were identified; 7 clusters were dominated not only by a single genus, most commonly Lactobacillus (45%) or Gardnerella (17%), but also by other taxa (25%). The remaining cluster had no dominant genus (13%).

conclusionDNA sequencing confirmed urinary bacterial DNA in many women with urgency urinary incontinence who had no signs of infection. Sequence status was associated with baseline urgency urinary incontinence episodes, treatment response, and posttreatment urinary tract infection risk.

Indexed as

Acetylcholine Release InhibitorsAdultAgedAge FactorsBacteriuriaBacteroidaceae InfectionsBody Mass IndexBotulinum Toxins, Type ACholinergic AntagonistsFemaleGardnerellaGram-Positive Bacterial InfectionsHumansLactobacillusMicrobiotaMiddle AgedAcetylcholine Release InhibitorsBotulinum Toxins, Type ACholinergic AntagonistsRNA, Ribosomal, 16Sbacteriamicrobiomemicrobiotaurgency urinary incontinenceurinary tract infection

Identifiers

PMID26210757
PMCPMC4556587
OpenAlexW1834656240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.